A Review published in Crit_Care highlights the need for prospective trials for treating right ventricular dysfunction in acute respiratory distress syndrome.
. A scoping review strategy was chosen based on a priori suspicion that there would be few randomized controlled trials or large observational studies to synthesize.MEDLINE, Embase, CINAHL, Web of Science, and the Cochrane Central Register of Controlled Trials databases were queried on July 21, 2022. Specific search terms can be found in Additional file
. In brief, articles describing both ARDS and any mention of right ventricular function or dysfunction were included in the search. Studies in the English language with patients 18 years and older were included from any year. Animal studies were excluded.All study types were eligible for inclusion except for review articles. Conference abstracts were excluded due to high risk of bias.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Four COVID-19 booster doses most effective way to prevent critical Omicron BA.5A study published in JAMA Network Open explores the protective efficacy of previous exposure to omicron subvariants and booster vaccination against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) omicron BA.5 infection.
Read more »
18-month-old baby 'critical' after being found unresponsive in Fulwood homeBREAKING: 18-month-old baby 'critical' after being found unresponsive in Fulwood home
Read more »
Intravenous methylprednisolone pulse therapy and the risk of in-hospital mortality among acute COVID-19 patients: Nationwide clinical cohort study - Critical CareBackground Steroids are widely used to modulate the inflammatory reactions associated with coronavirus disease 2019 (COVID-19); however, the optimal upper limit dose of steroid use for acute COVID-19 care remains unclear and currently available data may suffer from a time-dependent bias of no effectiveness or reversed causation given the desperate situation of treatment during this pandemic. Accordingly, the aim of this study was to elucidate the impact of intravenous pulse therapy with methylprednisolone (500 mg or greater per day) on the risk of in-hospital mortality among patients with COVID-19 by controlling for time-dependent bias. Methods We performed a prospective cohort study with 67,348 hospitalised acute COVID-19 patients at 438 hospitals during 2020–2021 in Japan. The impact of intravenous methylprednisolone pulse therapy on the risk of in-hospital mortality was examined based on hazard ratios (HRs) and 95% confidence intervals (95% CIs), with stratification according to the status of invasive mechanical ventilation (iMV). Time-dependent bias was controlled for in a marginal structural model analysis, with reference to patients without methylprednisolone therapy. Results During the study period, 2400 patients died. In-hospital mortality rates of iMV-free patients without or with methylprednisolone pulse therapy were 2.3% and 19.5%, and the corresponding values for iMV-receiving patients were 24.7% and 28.6%, respectively. The marginal structural model analysis showed that intravenous pulse therapy with methylprednisolone was associated with a lower risk of in-hospital mortality among patients receiving-iMV (HR 0.59; 95% CI 0.52–0.68). In contrast, pulse therapy with methylprednisolone increased the risk of in-hospital mortality among iMV-free patients (HR 3.38; 95% CI 3.02–3.79). The benefits of pulse therapy for iMV-receiving patients were greater than in those treated with intermediate/higher doses (40–250 mg intravenously) of methylprednisolone (HR 0.8
Read more »
How Israel's Far Right Is Prompting Outrage from the DiasporaPro-Israel organizations and advocates around the world have come out against the country's illiberal turn.
Read more »
Steiner doesn't 'really care about' Drive to SurviveFormulaNerds.com — Latest News — Günther Steiner has become - perhaps unwillingly - the star of the Formula 1 documentary Drive to Survive. He strongly criticises Mick Schumacher in the current season, but Steiner does not regret his statements.
Read more »
Connecticut Woman 1st Non-Vermonter Granted Assisted Suicide Right ThereLynda Bluestein has terminal cancer and knows she’ll likely die soon, but until Tuesday, she didn’t know if she’d be able to choose how or when and whether her family, friends and dog would be with her when the time comes. The 75-year-old from Bridgeport, Connecticut, reached a settlement with the state of Vermont that will allow her to be…
Read more »